Clinical Trials Logo

Alcohol Withdrawal Syndrome clinical trials

View clinical trials related to Alcohol Withdrawal Syndrome.

Filter by:

NCT ID: NCT05438641 Completed - Clinical trials for Alcohol Withdrawal Syndrome

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

Start date: August 2013
Phase:
Study type: Observational

Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when admitted to medical/surgical units. During the last 15 months, the investigators have implemented a benzodiazepine-sparing management approach with very positive clinical outcomes. The BZDP-sparing protocol consists of a combination of alpha-2 agonist and/or anticonvulsant agents; all currently being used for the management of other medical conditions. This project intends to collect and analyze the data of all subjects managed with this approach to better understand its effectiveness and assess for potential adverse effects.

NCT ID: NCT04973202 Completed - Clinical trials for Alcohol Use Disorder

Portrayal of Hospital Alcohol Detoxification in France

Alcostop
Start date: May 1, 2021
Phase:
Study type: Observational

Even if hospital alcohol detoxifications are frequent in France, their caracteristicscharacteristics remain unknown. The investigators aim to describe the clinical and paraclinical caracteristicscharacteristics of their patients, their length and geographical repartition, etc… The investigators also aim to evaluate factors associated with longer stays or ulterior re-hospitalization for the same reason. Finally, The investigators aim to compare the stays by facility type.

NCT ID: NCT03788889 Withdrawn - Clinical trials for Alcohol Withdrawal Syndrome

Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine

PKAT
Start date: April 12, 2019
Phase: Phase 4
Study type: Interventional

The goal of this study will aim to determine if adding phenobarbital or ketamine to a symptom-triggered benzodiazepine regimen decreases the rate of intensive care unit admissions during the treatment of alcohol withdrawal syndrome when compared to symptom-triggered benzodiazepine therapy alone.

NCT ID: NCT03235531 Recruiting - Clinical trials for Alcohol Use Disorder

Assessment of Valproate on Ethanol Withdrawal

PAVE
Start date: July 11, 2017
Phase: Phase 4
Study type: Interventional

Alcohol use disorder, or heavy drinking, is commonly seen in patients who present to trauma centers. These patients are at risk for Alcohol Withdrawal Syndrome (AWS), which is collection of symptoms that can range from anxiety and restlessness to seizures, delirium and even death. The Clinical Institute Withdrawal Assessment (CIWA) tool is routinely used to assess alcohol withdrawal symptoms. Benzodiazepines (BZD) are commonly administered to trauma patients who exhibit symptoms of AWS based on the CIWA scoring system. Although these medications have proven efficacy, they can also have negative side effects which may affect recovery. Valprate (VPA) is a medication which may have efficacy in management of AWS symptoms, thus ameliorating or preventing the need for BZD administration. This trial will study the effectiveness of VPA in the prevention of AWS symptoms by comparing the amount of BZD use in trauma patients who receive BZD treatment as indicated by CIWA scores with patients who receive prophylactic VPA therapy in addition to BZD as indicated by CIWA scores.

NCT ID: NCT03033823 Completed - Clinical trials for Alcohol Withdrawal Syndrome

MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)

MAGMA
Start date: November 16, 2017
Phase: Phase 3
Study type: Interventional

This study examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of alcohol withdrawal symptoms among inpatients requiring pharmacological treatment of their AWS. This double blind randomized multicenter clinical trial planned to treat half of participants as usal plus placebo and the other half as usual plus magnesium.

NCT ID: NCT03012815 Completed - Clinical trials for Alcohol Withdrawal Syndrome

Gabapentin for Alcohol Withdrawal Syndrome

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

The current "gold-standard" for the management of alcohol withdrawal syndrome (AWS) is symptom-triggered administration of benzodiazepines. This method of treatment has several drawbacks that have been described in the literature. Thus benzodiazepine sparing agents have been evaluated for use in AWS. One of these agents that has not only shown benefit for AWS but also benefits on complete abstinence, reducing a return to heavy drinking, and cravings is gabapentin. In clinical practice at Mayo Clinic gabapentin is used for this purpose. Due to the limited reports of the safety and efficacy of a protocol involving gabapentin for AWS, a study to compare gabapentin to symptom-triggered lorazepam will be completed.

NCT ID: NCT02146716 Completed - Clinical trials for Alcohol Withdrawal Syndrome

Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.

RESC
Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of RESC study is to assess the efficacy of Energetic Resonance by Cutaneous Stimulation on alcohol withdrawal symptoms measured by CUSHMAN score and in a second time to measure the benzodiazepine amount prescribed during the withdrawal time.

NCT ID: NCT02090504 Completed - Alcohol Dependence Clinical Trials

Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome

GATE I
Start date: February 2002
Phase: Phase 4
Study type: Interventional

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. Aim of this phase IV, multicenter randomized double-blind, double dummy study is to evaluate the efficacy of SMO in comparison to oxazepam in the treatment of alcohol withdrawal symptoms (AWS).

NCT ID: NCT02052440 Terminated - Clinical trials for Alcohol Withdrawal Syndrome

Preventing Alcohol Withdrawal Syndrome With Oral Baclofen

Start date: March 15, 2014
Phase: Phase 3
Study type: Interventional

Adult medical/surgical inpatient hospital care is more difficult and more expensive when complicated by alcohol dependency (AD), especially for patients who develop alcohol withdrawal syndrome (AWS). AWS can be mild, moderate or severe. The Severity of Ethanol Withdrawal Scale (SEWS) is tool used to assess severity and is the current standard of care for both monitoring and treating AWS at Denver Health. Moderate/severe AWS (i.e., SEWS ≥ 7) has important clinical implications and requires pharmacological treatment. At present, there are no safe and effective options for preventing AWS in at-risk inpatients. Baclofen is a GABA-B receptor agonist that has been used in the alleviation of spasticity in patients with multiple sclerosis since the 1970s. Baclofen has shown promise in the management of alcohol dependency in preclinical and clinical studies. We propose to examine baclofen in the prevention/amelioration of AWS in adult medical inpatients. The investigators hypothesize that Baclofen, as compared to placebo, will significantly reduce the number of adult inpatients with AD who will develop moderate/severe AWS (SEWS ≥ 7) when assessed at 72 hours after enrollment. Further the investigators hypothesize that Baclofen, as compared to placebo, will significantly reduce the need for symptom-triggered benzodiazepine administration during the 72 hours of hospitalization. These hypotheses will be tested in adult inpatients who are determined to be at risk for alcohol withdrawal and are subsequently placed on the SEWS monitoring and treatment protocol. These patients will be randomized to baclofen 10mg three times daily vs placebo.

NCT ID: NCT01652326 Completed - Clinical trials for Alcohol Withdrawal Syndrome

Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome

Start date: July 2012
Phase: N/A
Study type: Observational

The overarching goal of this project is to improve the clinical quality of patients with Benzodiazepine-resistant alcohol withdrawal syndrome.